Literature DB >> 20010866

Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.

S H Lee1, K H Yoo, K W Sung, H H Koo, Y J Kwon, M M Kwon, H J Park, B-K Park, Y Y Kim, J A Park, H J Im, J J Seo, H J Kang, H Y Shin, H S Ahn.   

Abstract

Four hundred and sixty-seven hematopoietic stem cell transplantations (HSCTs) (217 autologous and 250 allogeneic HSCT) were performed in 374 children at four pediatric HSCT centers in Korea from January 2005 to December 2007. Among 467 transplants, veno-occlusive disease (VOD) developed in 72 transplants (15.4%) at a median of 10 days after HSCT. Multivariate analysis showed that BU or TBI-containing regimen (P=0.002), VOD prophylaxis without lipo-prostaglandin E1 (PGE1) (P=0.012), number of previous HSCT (P=0.014), and pretransplant serum ferritin (P=0.018) were independent risk factors for developing VOD. Mean serum ferritin levels were significantly higher in HSCT with VOD (2109.6+/-2842.5 ng/ml) than in HSCT without VOD (1315.9+/-1094.4 ng/ml) (P<0.001). The relative risk of death within 100 days of HSCT in transplants with VOD compared with transplants without VOD was 3.39 (confidence interval: 1.78-6.45). Our results suggest that lipo-PGE1 might have a protective effect against the development of VOD, and pretransplant serum ferritin could act as a risk factor for VOD. A larger prospective study is needed to confirm a possible role of lipo-PGE1 and iron chelation therapy in reducing the incidence of VOD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20010866     DOI: 10.1038/bmt.2009.349

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  Role of Initiating Supportive Care Preceding Veno-occlusive Disease Diagnosis Following Allogeneic Hematopoietic Stem Cell Transplantation in Children.

Authors:  Patricia Rayner; Jessica L Spruit; Roland Chu; Maxim Yankelevich; Meret Henry; Yaddanapudi Ravindranath; Süreyya Savaşan
Journal:  J Pediatr Hematol Oncol       Date:  2019-08       Impact factor: 1.289

Review 2.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2012-04-24

3.  Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.

Authors:  Aimee C Talleur; Brandon M Triplett; Sara Federico; Ewelina Mamcarz; William Janssen; Jianrong Wu; David Shook; Wing Leung; Wayne L Furman
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-18       Impact factor: 5.742

4.  Predictors of the development of surgical complications among hematopoietic stem cell transplantation recipients.

Authors:  Iyad Anabtawi; Fawzi Abdelrahman; Ahamd Alomari; Murad Ba'ba'; Mahmoud Al Masri
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

5.  Does iron overload really matter in stem cell transplantation?

Authors:  Philippe Armand; Marie-Michele Sainvil; Haesook T Kim; Joanna Rhodes; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ellis J Neufeld; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

6.  Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? : Prospective evaluation of pediatric EBMT criteria for VOD.

Authors:  Zofia Szmit; Ewa Gorczynska; Anna Król; Marek Ussowicz; Monika Mielcarek-Siedziuk; Igor Olejnik; Anna Panasiuk; Krzysztof Kałwak
Journal:  Bone Marrow Transplant       Date:  2020-05-12       Impact factor: 5.483

7.  Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

Authors:  Kristina M Brooks; Paul Jarosinski; Thomas Hughes; Elizabeth Kang; Nirali N Shah; John B Le Gall; Dennis D Hickstein; Suk See De Ravin; Jomy M George; Parag Kumar
Journal:  J Clin Pharmacol       Date:  2017-12-14       Impact factor: 3.126

8.  Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Claudia Seifert; Susan Wittig; Clemens Arndt; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-22       Impact factor: 4.553

9.  Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Authors:  Carlos Vallejo; Montserrat Batlle; Lourdes Vázquez; Carlos Solano; Antonia Sampol; Rafael Duarte; Dolores Hernández; Javier López; Montserrat Rovira; Santiago Jiménez; David Valcárcel; Vicente Belloch; Mónica Jiménez; Isidro Jarque
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

10.  Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.

Authors:  Paul G Richardson; Vincent T Ho; Sergio Giralt; Sally Arai; Shin Mineishi; Corey Cutler; Joseph H Antin; Nicole Stavitzski; Dietger Niederwieser; Ernst Holler; Enric Carreras; Robert Soiffer
Journal:  Ther Adv Hematol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.